Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| ALDEYRA THERAPEUT (NASDAQ: ALDX) | Delayed: 0.71 +0.04 (5.97%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.67 | 52 Week High | $8.19 | |||
| Open | $0.67 | 52 Week Low | $3.39 | |||
| Day High | $0.73 | P/E | N/A | |||
| Day Low | $0.67 | EPS | $0.00 | |||
| Volume | 153,440 | |||||
